Código QR (código de barras bidimensional)

Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis

Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research design and methods: Herein, we performed a meta-analysis aimed to evaluate any gr...

ver descrição completa

Na minha lista:
Principais autores: Gennaro Gadaleta-Caldarola, Laura Lanotte, Stefania Infusino, Arianna Gadaleta-Caldarola, Francesca Matilde Schipilliti, Claudia Citrigno, Cataldo Petrarota, Antonio Cusmai, Alessandro Rizzo
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2023-01-01
coleção:Cancer Treatment and Research Communications
Assuntos:
Breast cancer
Triple-negative breast cancer
Antibody drug conjugates
Datopotamab deruxtecan
Dato-Dxd
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2468294223000977
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados